Investor Relations

Sonoma Keeps You Informed

Sign up for email alerts to receive Sonoma updates including press releases, filings and special announcements straight to your inbox.

We're sorry, but this form has spam protection that requires JavaScript to be enabled to work correctly. If you'd like to contact us via this form, please enable scripts in your browser and reload the page.

First Name

Last Name

Email Address

Contact Type:

Sign me up for:

All Press Releases

All SEC Filings

10-K & 10-Q Reports

Current Reports

Insider Transactions

Proxy Information

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

Nov 11, 2024

View All News

Q2 2025

Quarter Ended Sep 30, 2024

Earnings Release

PDF HTML

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

Fiscal Year Ended Mar 31, 2024

View Filing

Stock Information

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma’s headquarters are in Boulder, Colorado, with manufacturing operations in Jalisco, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.

Sonoma Investor Presentation October 2024

Download Sonoma Investor Presentation October 2024

Investor Contact Information

Company

Sonoma Pharmaceuticals, Inc.
5445 Conestoga Court
Suite 150
Boulder, CO 80301
T: 800-759-9305
ap@sonomapharma.com